Pipeline
Bringing Hope to Life through our NMDA Platform
We focus on serious, life-threatening conditions with major unmet medical needs. Our growing pipeline is powered by our proprietary, dual-targeted mechanism of action, which safely modulates the NMDA and 5HT2A receptors.
As we unlock our discoveries about the role of NMDA receptors throughout the human body, we leverage that research to bring hope to people with:
- Depression
- Suicidality
- Chronic Pain
- PTSD
Therapeutic Areas by Population Size in United States
Sources:
- National Institute of Mental Health, https://www.nimh.nih.gov/health/statistics/bipolar-disorder
- US Dept of Veteran Affairs, https://www.ptsd.va.gov/understand/common/common_adults.asp
- Centers for Disease Control and Prevention, https://www.cdc.gov/mmwr/volumes/72/wr/mm7215a1.htm
BIPOLAR DEPRESSION & SUICIDAL IDEATION
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Severe Bipolar Depression with Recently Suicidal Patients post stabilization
NRX-100™ (IV Ketamine)
Phase 3
*Collaboration Agreement with Study Leadership of two well-powered, academic clinical trialsNDA Filing H1 2024 | PDUFA est. 2024
Treatment of Suicidal Treatment-Resistant Bipolar Depression
NRX-101™
Phase 3
Enrollment Completed, Phase 2b/3 – Partnered w/ Alvogen Inc. & Lotus Pharma CHRONIC PAIN WITH DEPRESSION
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Chronic Back Pain
D-Cycloserine (DCS)
Phase 3
200 person, independent trial funded by DODPending Data Readout
Chronic Nociceptive Pain
NRX-101™
Phase 2
IND Approved | Applied to NIH EPICNET & HEAL POST TRAUMATIC STRESS DISORDER (PTSD)
Indication
Preclinical
Phase 1
Phase 2
Phase 3
PTSD in patients with Depression & Suicidality
NRX-101™
Phase 2
Nonclinical Evidence | Clinical Planning COMPLICATED UTI
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Complicated UTI incl. Pyelonephritis
NRX-101™
Phase 2
In Vitro Data | QIDP and Fast Track granted
Follow Us
Keep up with the latest news and updates about NRx through social media.